Home | Articles | Nutrition | New drug highly promising for weight loss

New drug highly promising for weight loss

A newly developed fat loss drug might be the answer to your shredding woes.

On average, subjects in a study conducted by scientists at the University of Leeds in England, dropped 5kg over a 12-week period after receiving weekly doses of semaglutide, a drug currently in development by a Danish pharmaceutical company to treat diabetes.

“What was striking was the potency of the drug’s action,” says John Blundell, lead researcher in the study.

“We saw results in 12 weeks which may take as long as six months with other anti-obesity medication. The drug reduced hunger but also cravings for food and the sensation of wanting to eat — and these had previously been thought to stem from different parts of the brain.”

Semaglutide’s chemical structure is similar to the naturally-occuring hormone GLP-1 which is believed to act on the appetite control centre in the hypothalamus in the brain to reduce feelings of hunger.

According to Blundell the study, which was recently published in the journal Diabetes, Obesity and Metabolism, set out to probe whether the drug could also be manufactured to fight obesity by acting on the brain’s appetite control receptors.

“A drug that reduces daily food intake by about a quarter with a substantial reduction in body fat will help some people to feel more in control of their lives and will help to prevent the onset of poor health that often arises from obesity,” says Blundell.

Semaglutide is in the advanced stages of development and not yet available.

Check Also

Is a low-carb diet superior to a low-fat one?

In a new long-term diet study where magnetic resonance imaging (MRI) imaging technology was used ...

Diet optimal in fighting disease, death

Research in over 135,000 people across five continents has shown that a diet low in ...

A link between sugar and cancer

A nine-year research project has led to a breakthrough in cancer research. Researchers have determined ...

Leave a Reply

Your email address will not be published. Required fields are marked *

Skip to toolbar